bioRxiv Science⌕ Search
Home/Archive/bioRxiv

bioRxiv · 10.1101/2022.07.17.500327

Insight parameter drug design for human beta-tryptase inhibition integrated molecular docking, QSAR, molecular dynamics simulation, and pharmacophore modelling studies of alpha-keto--oxadiazoles

Yu, C. X.·Tan, J. W.·Imran, S.·Rullah, K.·Tham, C. L.
View original source ↗Export metadata ↓

Abstract

Dengue hemorrhagic fever (DHF) is life-threatening severe dengue with a hallmark of vascular leakage. A mast cell protease, {beta}-tryptase, has been found to promote vascular leakage in DHF patients, which could be a potential target for the treatment of DHF. This study aims to develop a theoretical background for the design and selection of {beta}-tryptase inhibitors through these approaches: two-dimensional quantitative structure-activity relationships (2D-QSAR) study, molecular docking analysis, molecular dynamics (MD) simulation, and structure-based pharmacophore modelling (PM). A total of 34 a-keto-[1,2,3]-oxadiazoles scaffold-based compounds, obtained from a past study, were used to generate 2D-QSAR models by Genetic Function Approximation (GFA). The generated 2D-QSAR models were used to investigate the relationships between the molecular structure and the potency of {beta}-tryptase inhibition. Molecular docking explores the binding affinities and binding interactions of the a-keto-[1,2,3]-oxadiazoles scaffold-based compounds with {beta}-tryptase (PDB Code 4A6L) by the CDOCKER tool in Discovery Studio. In addition, MD simulation was performed using GROMACS on the docked complex of the reported most active compound, compound 11e, to study the binding mechanism of the compound towards {beta}-tryptase. Finally, a structure-based pharmacophore model was generated from the same docked complex to identify the important features that contribute positively to the inhibitory activity of the compound towards {beta}-tryptase. The best 2D-QSAR model has demonstrated statistically significant results through its r2, q2, and r2 (pred) values of 0.9077, 0.733, and 0.8104, respectively. The docking results of compound 11e showed lower CDOCKER energy than the 4A6L co-crystallised ligand, indicating good binding affinity. Furthermore, compound 11e has a similar binding pattern as the 4A6L co-crystallised ligand, which involves the binding of active residues such as Asp207, SER208, and GLY237. The MD simulation shows that the 4A6L-compound 11e complex has RMSD below 2[A] throughout the 100ns of simulation, indicating that the docked complex is stable. Besides, MD simulation showed that the inhibitory potency of compound 11e is contributed by hydrogen bonding with 4A6L active site residues, which are ASP207, SER208, and GLY237. The best pharmacophore model identified features that contribute to the inhibitory potency of a compound, which included hydrogen bond acceptor, ionic interaction, hydrophobic interaction, and aromatic ring. This study has fundamentally supplied valuable insight and knowledge for developing novel chemical compounds with improved inhibitory ability against human {beta}-tryptase. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=91 SRC="FIGDIR/small/500327v1_ufig1.gif" ALT="Figure 1"> View larger version (26K): org.highwire.dtl.DTLVardef@1e277c4org.highwire.dtl.DTLVardef@1250185org.highwire.dtl.DTLVardef@86fed8org.highwire.dtl.DTLVardef@c54035_HPS_FORMAT_FIGEXP M_FIG C_FIG DENV induces mast cell degranulation to release mediators, such as {beta}-tryptase. {beta}-Tryptase has been reported to promote plasma leakage, which is the hallmark of dengue hemorrhagic fever (DHF). Thus, {beta}-tryptase could be a promising target for the treatment of DHF. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=190 SRC="FIGDIR/small/500327v1_ufig2.gif" ALT="Figure 2"> View larger version (38K): org.highwire.dtl.DTLVardef@1fa7ff9org.highwire.dtl.DTLVardef@e7f1f8org.highwire.dtl.DTLVardef@1bf0175org.highwire.dtl.DTLVardef@f8d033_HPS_FORMAT_FIGEXP M_FIG C_FIG In this study, computer-aided drug design was used to examine the structure-activity relationship and binding mechanisms of {beta}-tryptase inhibitors reported in a past study. Finally, theoretical background for the design of {beta}-tryptase inhibitors was built.

Explore related subjects

biochemistryPreprint

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Yu, C. X., Tan, J. W., Imran, S., Rullah, K., Tham, C. L.. 2022-07-17. Insight parameter drug design for human beta-tryptase inhibition integrated molecular docking, QSAR, molecular dynamics simulation, and pharmacophore modelling studies of alpha-keto--oxadiazoles. https://doi.org/10.1101/2022.07.17.500327

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Hierarchical cysteine oxidation controls reversible amyloid formation in an ankyrin repeat protein

The formation of amyloids, including functional amyloids, is observed for an increasing number of proteins but the molecular mechanisms that control this structural transition remain poorly understood. Here we report that the kinase inhibitor protein P18 (drP18) from Danio rerio (zebrafish), which contains two cysteine residues, undergoes a complex and hierarchical redox switch that strictly governs reversible amyloid formation. We identify cysteine 50 (C50) acting as a regulatory residue. Upon oxidation, C50 forms an intramolecular disulfide bond with the executioner cysteine 128 (C128), thereby blocking it. C50 can become S-glutathionylated, and upon oxidation, C128 then forms intermolecular disulfides that lead to rapid transition into amyloid fibrils. S-glutathionylation of C50 therefore enables amyloid formation of drP18 and the outcome is oxidant-dependent with diamide, hydrogen peroxide, peroxymonocarbonate and hypothiocyanous acid each leading to amyloid assembly with distinct kinetics and morphologies. These amyloids are fully reversible, where disulfide reduction is leading to disassembly. Whereas monomeric drP18 inhibits CDK4-mediated retinoblastoma phosphorylation, the amyloid conformation abolishes this inhibition, and reduction restores both structure and function. Expression of drP18 in zebrafish embryos yields Congo red-positive, oxidation-dependent aggregates in vivo. Together, our findings show that a regulatory cysteine controls an executioner cysteine to induce reversible, functional amyloid formation, revealing that proteins can encode sophisticated mechanisms to control amyloid assembly.

biochemistry↗
bioRxiv2026

Snapshots from the Catalytic Landscape of Chalcone Isomerase

Chalcone isomerase (CHI) catalyzes the cyclization of 3-ring scaffolds of flavonoids, a class of plant-based natural products important for nutrition and disease prevention. A persistent question has been whether the enzyme uses dynamics to facilitate conformational rearrangements of substrates within the active site. To help resolve this question, CHI was crystallized with phloretin, a flexible substrate analogue that cannot undergo cyclization. The crystal structure possesses eight protein molecules per asymmetric unit, revealing different active site conformations that accommodate different bound conformers of phloretin. Together, the structural snapshots depict a series of coordinated, dynamic chemical interactions that lower barriers to substrate rearrangements approaching bond formation. Differential scanning fluorimetry combined with mutational analysis and enzyme kinetics further confirm that phloretin binds to the enzyme active site and that it acts as a competitive inhibitor of CHI. Together these findings answer outstanding questions about the flexibility and dynamics of CHI catalysis, information that may be useful for future biosynthetic design and enzyme engineering goals. Overall, this work supports a catalytic model in which the CHI enzyme operates as a dynamic ensemble of structures necessary to facilitate catalytic substrate rearrangements.

biochemistry↗
bioRxiv2026

Structures of pUG-fold RNA bound to DNMT1 reveal a mechanism for RNA-mediated epigenetic regulation

Many chromatin-associated proteins have been found to bind RNA as a means of epigenetic regulation. Specifically, DNA methyltransferase 1 (DNMT1), which maintains cytosine methylation at CpG dinucleotides, is inhibited by RNA at transcribed DNA loci in cells. However, the mechanisms by which RNA binds DNMT1 and inhibits its activity remain unknown. Here, we determine a series of cryogenic electron microscopy (cryo-EM) structures of human DNMT1 bound to pUG-fold RNA, a non-canonical G-quadruplex previously observed to inhibit activity, revealing two distinct RNA-binding modes. The pUG-fold RNA binds the surface of DNMT1 in its autoinhibited conformation across a positively charged surface between the methyltransferase domain and the CXXC domain, and it binds directly in the active site of an open DNMT1 conformation. RNA binding is sterically incompatible with substrate DNA engagement in both states. Our 2.5 [A] structure captures the intricate network of hydrogen bonds and electrostatic interactions between amino acids in the methyltransferase domain and the tetrad layers of pUG-fold RNA. Metadynamics molecular dynamics simulations provide an orthogonal view of the conformational landscape of DNMT1, revealing the two distinct RNA-binding modes. Furthermore, our analysis of published DNMT1 RIP-seq and eCLIP-seq data confirms that DNMT1-interacting RNAs in cells exhibit a strong propensity to form non-canonical G-quadruplex RNA structures. Collectively, our study provides the first structural basis for pUG-fold RNA recognition by a protein and illustrates how cryo-EM and AI-based methods for protein and RNA structure prediction synergize to inform the mechanism of RNA-mediated regulation of DNMT1.

biochemistry↗